Drug intelligence / Profile preview

Lansoprazole + naproxen + aspirin

Development stage
Phase 3
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

Lansoprazole + naproxen + aspirin is a combination therapy that includes three active pharmaceutical ingredients: - Lansoprazole, a proton pump inhibitor (PPI) that reduces gastric acid secretion by inhibiting the Gastric H+/K+ ATPase enzyme in gastric parietal cells. - Naproxen, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties, which works by inhibiting Cyclooxygenase 1 (COX-1) and Cyclooxygenase 2 (COX-2), thereby reducing prostaglandin synthesis involved in inflammation and pain. - Aspirin, an antiplatelet agent and NSAID that irreversibly inhibits cyclooxygenase enzymes (primarily COX-1), leading to decreased thromboxane A2 production for platelet aggregation inhibition as well as anti-inflammatory effects. This combination is used primarily for patients with osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis who require long-term NSAID therapy but are at increased risk of gastrointestinal ulcers or cardiovascular events. Lansoprazole helps protect the stomach lining from ulceration caused by chronic NSAID use. The addition of low-dose aspirin may be indicated for cardiovascular prophylaxis in patients at risk[1][3][5][6].

Brand names
Prevacid NapraPAC
Other names
lansoprazole and naproxenlansoprazole/naproxen/aspirin
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Lansoprazole + naproxen + aspirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lansoprazole + naproxen + aspirin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call